Form 4: Terns Pharmaceuticals Executive Acquires Shares and Stock Options

Melita Sun Jung, Chief Business Officer of Terns Pharmaceuticals, acquired 2,250 shares and 325,000 stock options.

Summary

• Melita Sun Jung, the Chief Business Officer of Terns Pharmaceuticals, has reported a transaction involving the company's stock.
• On November 30, 2024, Ms. Jung acquired 2,250 shares of common stock at a price of $5.11 per share through the company's Employee Stock Purchase Plan.
• Additionally, on January 30, 2025, Ms. Jung was granted stock options for 325,000 shares with an exercise price of $4.64.
• The stock options vest over four years, with 25% vesting on the first anniversary of January 1, 2025, and the remainder vesting monthly thereafter.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan demonstrates the executive's confidence in the company.
• The grant of stock options aligns the executive's interests with the long-term success of the company.

Future Outlook

The stock options vest over a four-year period, incentivizing the executive to contribute to the company's long-term growth.

Industry Context

This is a standard SEC Form 4 filing, which is common for executives of publicly traded companies when they acquire or dispose of company stock or options.

Comparison to Industry Standards

• Stock option grants and employee stock purchase plans are common forms of compensation for executives in the pharmaceutical industry.
• The vesting schedule of the stock options is typical, with a four-year vesting period.

Stakeholder Impact

• The stock and option transactions may have a minor positive impact on shareholder sentiment.
• The vesting schedule of the stock options incentivizes the executive to contribute to the company's long-term growth, which is beneficial for all stakeholders.

Key Dates

Keywords

Terns Pharmaceuticals, stock options, share acquisition, insider trading, Melita Sun Jung, executive compensation, employee stock purchase plan